G6057 HCPCS Level II code: Phenothiazine
CMS terminated G6057: its last date of service was Dec 31, 2015. It stays here for looking up older claims; newer services need a current code.
Official description
G6057Phenothiazine
Short description: Assay of phenothiazine
HCPCS · United States
Medicare details
The indicators CMS publishes with G6057 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Clinical lab fee schedule – Price subject to national limitation amount
- Type of service
- Diagnostic laboratory
- BETOS category
- Lab tests - other (Non-Medicare fee schedule)
- Lab certification
- Toxicology
- Added
- Jan 1, 2015
- Terminated after
- Dec 31, 2015
Where G6057 sits
- 1G codesProcedures and professional services
- 2Terminated G6057Phenothiazine
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code G6057 still valid?
No. CMS terminated G6057; its last date of service was Dec 31, 2015. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover G6057?
CMS lists G6057’s Medicare coverage as “Carrier judgment” and its pricing as “Clinical lab fee schedule – Price subject to national limitation amount”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G6057
All G codesG6051FlurazepamG6052MeprobamateG6053MethadoneG6054MethsuximideG6055NicotineG6056Opiate(s), drug and metabolites, each procedureG6058Drug confirmation, each procedureG8126Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phaseG8127Patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phaseG8128Clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measureG8395Left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic functionG8396Left ventricular ejection fraction (lvef) not performed or documented